Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1986 Dec;30(6):945–947. doi: 10.1128/aac.30.6.945

Epidemiology of intestinal colonization by members of the family Enterobacteriaceae resistant to cefotaxime in a hematology-oncology unit.

M H Prevot, A Andremont, H Sancho-Garnier, C Tancrede
PMCID: PMC180626  PMID: 3813517

Abstract

Intestinal colonization by members of the family Enterobacteriaceae resistant to cefotaxime was surveyed for 3 years in a hematology-oncology unit. Of 416 patients, 66 (15.9%) were colonized, each with a different strain. The incidence of intestinal carriage was not correlated with cefotaxime consumption in the ward but was strongly associated with individual exposure to cefotaxime.

Full text

PDF
945

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andremont A., Sancho-Garnier H., Tancrede C. Epidemiology of intestinal colonization by members of the family Enterobacteriaceae highly resistant to erythromycin in a hematology-oncology unit. Antimicrob Agents Chemother. 1986 Jun;29(6):1104–1107. doi: 10.1128/aac.29.6.1104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Benn R. A., Kemp R. J. Effect of antibiotic use on the incidence of cephalosporin resistance in two Australian hospitals. J Antimicrob Chemother. 1984 Sep;14 (Suppl B):71–76. doi: 10.1093/jac/14.suppl_b.71. [DOI] [PubMed] [Google Scholar]
  3. Collatz E., Gutmann L., Williamson R., Acar J. F. Development of resistance to beta-lactam antibiotics with special reference to third-generation cephalosporins. J Antimicrob Chemother. 1984 Sep;14 (Suppl B):13–21. doi: 10.1093/jac/14.suppl_b.13. [DOI] [PubMed] [Google Scholar]
  4. Guy H., Chavanet P., Portier H., Kazmierczak A., Cortet P. Traitement par une association céfotaxime-amikacine des épisodes infectieux des leucémies aiguës de l'adulte en aplasie thérapeutique. Nouv Presse Med. 1981 Feb 26;10(8):654–656. [PubMed] [Google Scholar]
  5. Jarlier V., Bismuth R., Nicolas M. H., Nguyen J., Truffot C., Grosset J. Survey of the phenotypes of susceptibility to beta-lactams in Enterobacteriaceae at the Pitie-Salpetriere Hospital. J Antimicrob Chemother. 1984 Sep;14 (Suppl B):59–65. doi: 10.1093/jac/14.suppl_b.59. [DOI] [PubMed] [Google Scholar]
  6. Lambert-Zechovsky N., Aufrant C., Bingen E., Blum C., Proux M. C., Mathieu H. Cefotaxime in children: efficacy, tolerance and effect on the intestinal bacterial flora. J Antimicrob Chemother. 1980 Sep;6 (Suppl A):235–242. doi: 10.1093/jac/6.suppl_a.235. [DOI] [PubMed] [Google Scholar]
  7. López E. L., Bonesana N. F., Rubeglio E., Schugurensky A., Sommersguter G., Grinstein S. Cefotaxime therapy in children with serious infections associated with reduced host defense mechanisms. J Antimicrob Chemother. 1980 Sep;6 (Suppl A):249–253. doi: 10.1093/jac/6.suppl_a.249. [DOI] [PubMed] [Google Scholar]
  8. Mitsuhashi S., Inoue M., Masuyoshi S. Antibacterial activity of cefotaxime. J Antimicrob Chemother. 1980 Sep;6 (Suppl A):37–46. doi: 10.1093/jac/6.suppl_a.37. [DOI] [PubMed] [Google Scholar]
  9. Nauciel C., Philippon A., Ronco E., Pilliot J., Guenounou M., Paul G., Brunel D., Outin H. D. Septicémies à Enterobacter cloacae et E. aerogenes: émergence de variants résistants (céphalosporinase déréprimée) en cours de traitement par des céphalosporines de troisième génération. Presse Med. 1985 Mar 23;14(12):673–676. [PubMed] [Google Scholar]
  10. Richmond M. H. beta-Lactamase stability of cefotaxime. J Antimicrob Chemother. 1980 Sep;6 (Suppl A):13–17. doi: 10.1093/jac/6.suppl_a.13. [DOI] [PubMed] [Google Scholar]
  11. Sanders C. C., Sanders W. E., Jr Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future. Rev Infect Dis. 1983 Jul-Aug;5(4):639–648. doi: 10.1093/clinids/5.4.639. [DOI] [PubMed] [Google Scholar]
  12. Tancrede C. H., Andremont A. O., Leonard F. C. Epidemiology of enterobacteria resistant to cefotaxime in hospital. J Antimicrob Chemother. 1984 Sep;14 (Suppl B):53–57. doi: 10.1093/jac/14.suppl_b.53. [DOI] [PubMed] [Google Scholar]
  13. Tancrède C. H., Andremont A. O. Bacterial translocation and gram-negative bacteremia in patients with hematological malignancies. J Infect Dis. 1985 Jul;152(1):99–103. doi: 10.1093/infdis/152.1.99. [DOI] [PubMed] [Google Scholar]
  14. Wells C. L., Podzorski R. P., Peterson P. K., Ramsay N. K., Simmons R. L., Rhame F. S. Incidence of trimethoprim-sulfamethoxazole-resistant enterobacteriaceae among transplant recipients. J Infect Dis. 1984 Nov;150(5):699–706. doi: 10.1093/infdis/150.5.699. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES